May 2009 Br J Cardiol 2009;16:147–150
Gavin J Bryce, Christopher J Payne, Simon C Gibson, David B Kingsmore, Dominique S Byrne
Introduction Vascular disease is a systemic disorder, with 50–60% of patients undergoing peripheral vascular procedures having co-existent severe coronary artery disease and only 10% having normal coronary arteries.1,2 It is unsurprising, therefore, that vascular surgery is associated with a substantial risk of major adverse cardiovascular events (MACE) and death.2,3 Cardiac troponin I (cTnI) is a contractile protein that is released into the circulation after myocardial cell injury. Unlike other cardiac-related enzymes, cTnI is not found in skeletal muscle and is therefore a highly sensitive and specific marker of myocardial necrosis,4,5 a
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits